Clinical Challenges of Nosocomial Infections Caused by Antibiotic-Resistant Pathogens in Pediatrics

Seminars in Pediatric Infectious Diseases

Volumn 15, Issue 1, 2004, Pages 21-29

  Pong, Alice ^a   Bradley, John S ^a  

^a RADY CHILDREN'S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMPICILLIN; ANTIBIOTIC AGENT; BETA LACTAMASE; CEFAZOLIN; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; COLISTIN; COTRIMOXAZOLE; ERTAPENEM; IMIPENEM; LINEZOLID; MEROPENEM; OXACILLIN; PENICILLIN BINDING PROTEIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; PORIN; RIFAMPICIN; TEICOPLANIN; TIMENTIN; TOBRAMYCIN; VANCOMYCIN;

ACINETOBACTER; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTEREMIA; BACTERIAL MUTATION; CATHETER INFECTION; CHILD; ENTEROBACTER; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; FOOD AND DRUG ADMINISTRATION; HOSPITAL INFECTION; HUMAN; KLEBSIELLA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PNEUMONIA; PSEUDOMONAS AERUGINOSA; REVIEW; SERRATIA; STAPHYLOCOCCUS; URINARY TRACT INFECTION; WOUND INFECTION;

EID: 2442596085     PISSN: 10451870     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.spid.2004.01.005     Document Type: Review

References (94)

1. Hallahan AR, Shaw PJ, Rowell G, et al: Improved outcomes of children with malignancy admitted to a pediatric intensive care unit. Crit Care Med 28:3718-3721, 2000
2. Booy R, Habibi P, Nadel S, et al: Reduction in case fatality rate from meningococcal disease associated with improved health-care delivery. Arch Dis Child 85:386-390, 2001
3. Tenner PA, Dibrell H, Taylor RP: Improved survival with hospitalists in a pediatric intensive care unit. Crit Care Med 31:847-852, 2003
4. Stover BH, Shulman ST, Bratcher DF, et al: Nosocomial infection rates in US children's hospitals' neonatal and pediatric intensive care units. AMJ Infect Control 29:152-157, 2001
5. Sohn AH, Garrett DO, Sinkowitz-Cochran RL, et al: Prevalence of nosocomial infections in neonatal intensive care unit patients: Results from the first national point-prevalence survey. J Pediatr 139:821-827, 2001
6. Girouard S, Levine G, Goodrich K, et al: Pediatric Prevention Network: a multicenter collaboration to improve health care outcomes. Am J Infect Control 29:158-161, 2001
7. Meert KL, Long M, Kaplan J, et al: Alterations in immune function following head injury in children. Crit Care Med 23:822-828, 1995
8. Tarnok A, Schneider P: Pediatric cardiac surgery with cardiopulmonary bypass: pathways contributing to transient systemic immune suppression. Shock 16:24-32, 2001 (suppl)
9. Howard DH, Scott RD II, Packard R, et al: The global impact of drug resistance. Clin Infect Dis 36:4-10, 2003 (suppl)
10. Koch AL: Penicillin binding proteins, β-lactams, and lactamases: offensives, attacks, and defensive countermeasures. Crit Rev Microbiol 26:205-220, 2000
11. Recchia GD, Hall RM: Origins of the mobile gene cassettes found in integrons. Trends Microbiol 5:389-394, 1997
12. Leibert CA, Hall RM, Summers AO: Transposon Tn21, flagship of the floating genome. Microbiol Mol Rev 63:507-522, 1999
13. Fluit AC, Schmitz FJ: Class I integrons, gene cassettes, mobility, and epidemiology. Eur J Clin Microbiol Infect Dis 18:761-770, 1999
14. Bush K, Jacoby GA, Medeiros AA: A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 39:1211-1233, 1995
15. Bush K: New β-lactamases in Gram-negative bacteria: diversity and impact on the selection of antimicrobial therapy. Clin Infect Dis 32: 1085-1089, 2001
16. Livermore DM: Bacterial resistance: origins, epidemiology, and impact. Clin Infect Dis 36:11-23, 2003 (suppl)
17. Odeh R, Kelkar S, Hujer AM, et al: Broad resistance due to plasmid-mediated AmpC beta-lactamases in clinical isolates of Escherichia coli. Clin Infect Dis 35:140-145, 2002
18. st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 14:933-951, 2001
19. Nordmann P, Poirel L: Emerging carbapenemases in Gram-negative aerobes. Clin Microbiol Infect 8:321-331, 2002
20. Livermore DM: Beta-lactamases: quantity and resistance. Clin Microbiol Infect 3:10-19, 1997 (suppl)
21. Livermore DM: β-lactamases in laboratory and clinical resistance. Clin Microbiol Rev 8:557-584, 1995
22. Philippon A, Arlet G, Jacoby GA: Plasmid-determined AmpC-Type β-lactamases. Antimicrob Agents Chemother 46:1-11, 2002
23. Wright GD: Aminoglycoside-odifying enzymes. Curr Opin Microbiol 2:499-503, 1999
24. Miller GH, Sabatelli FJ, Hare RS, et al: The most frequent aminoglycoside resistance mechanisms-changes with time and geographic area: a reflection of aminoglycoside usage patterns? Aminoglycoside Resistance Study Groups. Clin Infect Dis 24:46-62, 1997 (suppl)
25. Sabtcheva S, Galimand M, Gerbaud G, et al: Aminoglycoside resistance gene ant(4')-Iib of Pseudomonas aeruginosa BM4492, a clinical isolate from Bulgaria. Antimicrob Agents Chemother 47:1584-1588, 2003
26. Cetinkaya Y, Falk P, Mayhall CG: Vancomycin-resistant enterococci. Clin Microbiol Rev 13:686-707, 2000
27. Chambers HF: Penicillin-binding protein-mediated resistance in pneumococci and staphylococci. J Infect Dis 179:353-359, 1999 (suppl)
28. Livermore DM: Antibiotic resistance in staphylococci. Int J Antimicrob Agents 16:S3-S10, 2000
29. Leclercq R: Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clin Infect Dis 34:482-492, 2002
30. Pootoolal Neu J, Wright GD: Glycopeptide antibiotic resistance. Annu Rev Pharmacol Toxicol 42:381-408, 2002
31. Martin R, Wilcox KR: Staphylococcus aureus with reduced susceptibility to vancomycin-United States, 1997. MMWR 46:765-766, 1997
32. Hooper DC: Emerging mechanisms of fluoroquinolone resistance. Emerg Infect Dis 7:337-341, 2001
33. Poole K: Efflux-mediated resistance to fluoroquinolones in Gram-negative bacteria. Antimicrob Agents Chemother 44: 2233-2241, 2000
34. Poole K: Multidrug efflux pumps and antimicrobial resistance in Pseudomonas aeruginosa and related organisms. J Mol Microbiol Biotechnol 3:255-264, 2001
35. Bambeke FV, Glupczynski Y, Plésiat P: Antibiotic efflux pumps in prokaryotic cells: occurrence, impact on resistance and strategies for the future of antimicrobial therapy. J Antimicrob Chemother 51:1055-1065, 2003
36. Lee A, Mao W, Warren MS, et al: Interplay between efflux pumps may provide either additive or multiplicative effects on drug resistance. J Bacteriol 182:3142-3150, 2000
37. Dé E, Baslé A, Jaquinod M, et al: A new mechanism of antibiotic resistance in Enterobacteriaceae induced by a structural modification of the major porin. Mol Microbiol 41:189-198, 2001
38. Hancock RE, Brinkman FS: Function of Pseudomonas porins in uptake and efflux. Annu Rev Microbiol 56:17-38, 2002
39. Calandra GB, Hesney M, Brown KR: Imipenem/cilastatin therapy of serious infections: a U. S. multicenter noncomparative trial. Clin Ther 7:225-238, 1985
40. Ehrhardt AF, Sanders CC: Beta-lactam resistance amongst Enterobacter species. J Antimicrob Chemother 32:1-11, 1993 (suppl)
41. Bagge N, Ciofu O, Hentzer M, et al: Constitutive high expression of chromosomal β-lactamase in Pseudomonas aeruginosa caused by a new insertion sequence (IS1669) located in ampD. Antimicrob Agents Chemother 46:3406-3411, 2002
42. Crowley B, Bened VJ, Dominech-Sánchez A: Expression of SHV-2 β-lactamase and of reduced amounts of OmpK36 porin in Klebsiella pneumoniae results in increased resistance to cephalosporins and carbapenems. Antimicrob Agents Chemother 46:3679-3682, 2002
43. Richards MJ, Edwards JR, Culver DH, et al: Nosocomial infections in pediatric intensive care units in the United States. Pediatrics 103:e39, 1999
44. Gaynes RP, Edwards JR, Jarvis WR, et al: Nosocomial infections among neonates in high-risk nurseries in the United States. Pediatrics 98:337-361, 1996
45. Kim YK, Pai H, Lee HJ, et al: Bloodstream infections by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in childrenepidemiology and clinical outcome. Antimicrob Agents Chemother 46:1481-1491, 2002
46. Gupta A: Hospital-acquired infections in the neonatal intensive care unit-Klebsiella pneumoniae. Semin Perinatol 26:340-345, 2002
47. Jang TN, Fung CP, Yang TL, et al: Use of pulsed-field gel electrophoresis to investigate an outbreak of Serratia marcescens infection in a neonatal intensive care unit. J Hosp Infect 48: 13-19, 2001
48. Liu SC, Leu HS, Yen MY, et al: Study of an outbreak of Enterobacter cloacae sepsis in a neonatal intensive care unitthe application of epidemiologic chromosome profiling by pulsed-field gel electrophoresis. AmJ Infect Control 30:381-385, 2002
49. Manning ML, Archibald LK, Bell LM, et al: Serratia marcescens transmission in a pediatric intensive care unit: a multifactorial occurrence. Am J Infect Control 29:115-119, 2001
50. Huang YC, Su LH, Wu TL, et al: Outbreak of Acinetobacter baumannii bacteremia in a neonatal intensive care unitclinical implications and genotyping analysis. Pediatr Infect Dis J 21: 1105-1109, 2002
51. Melamed R, Greenberg D, Porat N, et al: Successful control of an Acinetobacter baumannii outbreak in a neonatal intensive care unit. J Hosp Infect 53:31-38, 2003
52. Brown DG, Baublis J: Reservoirs of pseudomonas in an intensive care unit for newborn infants: mechanisms of control. J Pediatr 90:453-457, 1977
53. Foca M, Jakob K, Whittier S, et al: Endemic Pseudomonas aeruginosa infection in a neonatal intensive care unit. N Engl J Med 343:695-700, 2000
54. Hoque SN, Graham J, Kaufmann ME, et al: Chryseobacterium (Flavobacterium) meningosepticum outbreak associated with colonization of water taps in a neonatal intensive care unit. J Hosp Infect 47:188-192, 2001
55. Higgens CS, Murtough SM, Williamson E, et al: Resistance to antibiotics and biocides among non-fermenting Gram-negative bacteria. Clin Microbiol Infect 7:308-315, 2001
56. Jarvis WR, Thornsberry C, Boyce J, et al: Methicillin-resistant Staphylococcus aureus at children's hospitals in the United States. Pediatr Infect Dis 4:651-655, 1985
57. Storch GA, Rajagopalan L: Methicillin-resistant Staphylococcus aureus bacteremia in children. Pediatr Infect Dis 5:59-67, 1986
58. Hershow RC, Khayr WF, Smith NL: A comparison of clinical virulence of nosocomially acquired methicillin-resistant and methicillin-sensitive Staphylococcus aureus infections in a university hospital. Infect Control Hosp Epidemiol 13:387-393, 1992
59. Soriano A, Martinez A, Mensa J, et al: Pathogenic significance of methicillin resistance for patients with Staphylococcus aureus bacteremia. Clin Infect Dis 30:368-373, 2000
60. González C, Rubio M, Romero-Vivas J, et al: Bacteremic pneumonia due to Staphylococcus aureusa comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis 29:1171-1177, 1999
61. Romero-Vivas J, Rubio M, Fernandez C, et al: Mortality associated with nosocomial bacteremia due to methicillin-resistant Staphylococcus aureus. Clin Infect Dis 21:1417-1423, 1995
62. Haley RW, Cushion NB, Tenover FC, et al: Eradication of endemic methicillin-resistant Staphylococcus aureus infections from a neonatal intensive care unit. J Infect Dis 171:614-624, 1995
63. Reboli AC, John JF Jr, Levkoff AH: Epidemic methicillin-gentamicin-resistant Staphylococcus aureus in a neonatal intensive care unit. Am J Dis Child 143:34-39, 1989
64. Sheridan RL, Weber J, Benjamin J, et al: Control of methicillin-resistant Staphylococcus aureus in a pediatric burn unit. Am J Infect Control 22:340-345, 1994
65. Stover BH, Duff A, Adams G, et al: Emergence and control of methicillin-resistant Staphylococcus aureus in a children's hospital and pediatric long-term care facility. Am J Infect Control 20:248-255, 1992
66. Burns JL, Emerson J, Stapp JR, et al: Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin Infect Dis 27:158-163, 1998
67. Miall LS, McGinley NT, Brownlee KG, et al: Methicillin resistant Staphylococcus aureus (MRSA) infection in cystic fibrosis. Arch Dis Child 84:160-162, 2001
68. Fergie JE, Purcell K: Community-acquired methicillin-resistant Staphylococcus aureus infections in South Texas children. Pediatr Infect Dis J 20:860-863, 2001
69. Herold BC, Immergluck LC, Maranan MC, et al: Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA 279:593-598, 1998
70. Sattler CA, Mason EO Jr, Kaplan SL: Prospective comparison of risk factors and demographic and clinical characteristics of community-acquired, methicillin-resistant versus methicillin-susceptible Staphylococcus aureus infection in children. Pediatr Infect Dis J 21:910-916, 2002
71. Gorak EJ, Yamada SM, Brown JD: Community-acquired methicillin-resistant Staphylococcus aureus in hospitalized adults and children without known risk factors. Clin Infect Dis 29: 797-800, 1999
72. Malik RK, Montecalvo MA, Reale MR, et al: Epidemiology and control of vancomycin-resistant enterococci in a regional neonatal intensive care unit. Pediatr Infect Dis J 18:352-356, 1999
73. Lee HK, Lee WG, Cho SR: Clinical and molecular biological analysis of a nosocomial outbreak of vancomycin-resistant enterococci in a neonatal intensive care unit. Acta Paediatr 88: 651-654, 1999
74. Yüce A, Karaman M, Gulay Z, et al: Vancomycin-resistant enterococci in neonates. Scand J Infect Dis 33:803-805, 2001
75. Henning KJ, Delencastre H, Eagan J, et al: Vancomycin-resistant Enterococcus faecium on a pediatric oncology wardduration of stool shedding and incidence of clinical infection. Pediatr Infect Dis J 15:848-854, 1996
76. Singh-Naz N, Sleemi A, Pikis A, et al: Vancomycin-resistant Enterococcus faecium colonization in children. J Clin Microbiol 37:413-416, 1999
77. Gray JW, George RH: Experience of vancomycin-resistant enterococci in a children's hospital. J Hosp Infect 45:11-18, 2000
78. Nourse C, Murphy H, Byrne C, et al: Control of a nosocomial outbreak of vancomycin resistant Enterococcusfaecium in a paediatric oncology unitrisk factors for colonization. Eur J Pediatr 157:20-27, 1998
79. Ibrahim EH, Sherman G, Ward S, et al: The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 118:146-155, 2000
80. Iregui M, Ward S, Sherman G, et al: Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 122:262-268, 2002
81. Drusano GL: Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin Infect Dis 36:S42-S50, 2003 (suppl)
82. Kollef MH: An empirical approach to the treatment of multidrug-resistant ventilator-associated pneumonia. Clin Infect Dis 36:1119-1121, 2003
83. Hoban DJ, Biedenbach DJ, Mutnick AH, et al: Pathogen of occurrence and susceptibility patterns associated with pneumonia in hospitalized patients in North America: results of the SENTRY antimicrobial surveillance study (2000). Diagn Microbiol Infect Dis 45:279-285, 2003
84. Mathai D, Lewis MT, Kugler KC, et al: Antibacterial activity of 41 antimicrobials tested against over 2773 bacterial isolates from hospitalized patients with pneumonia: I-results from the SENTRY antimicrobial surveillance program (North America, 1998). Diagn Microbiol Infect Dis 39:105-116, 2001
85. Mathai D, Jones RN, Pfaller MA, et al: Epidemiology and frequency of resistance among pathogens causing urinary tract infections in 1,510 hospitalized patients: a report from the SENTRY antimicrobial surveillance program (North America). Diagn Microbiol Infect Dis 40:129-136, 2001
86. Burkhardt JE, Walterspiel JN, Schaad UB: Quinolone arthropathy in animals versus children. Clin Infect Dis 25:1196-1204, 1997
87. Levin AS, Barone AA, Penco J, et al: Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 28:1008-1011, 1999
88. Garnacho-Montero J, Ortiz-Leyba C, Jiménez-Jiménez FJ, et al: Treatment of multidrug-resistant Acinetobacter baumannii ventilator associated pneumonia (VAP) with intravenous colistina comparison with imipenem-susceptible VAP. Clin Infect Dis 36:1111-1118, 2003
89. Lai KK: Treatment of vancomycin-resistant Enterococcus faecium infections. Arch Intern Med 156:2579-2584, 1996
90. Low DE: Quinupristin/dalfopristin: spectrum of activity, pharmacokinetics, and initial clinical experience. Microb Drug Resist 1:223-234, 1995
91. Birmingham MC, Rayner CR, Meagher AK, et al: Linezolid for the treatment of multidrug-resistant, Gram-positive infections: experience from a compassionate-use program. Clin Infect Dis 36:159-168, 2003
92. Herrero IA, Issa NC, Patel R: Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium. N Engl J Med 346:867-869, 2002
93. Karlowsky JA, Draghi DC, Jones ME, et al: Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001. Antimicrob Agents Chemother 47:1681-1688, 2003
94. Gales AC, Jones RN, Forward KR, et al: Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients geographic patterns, epidemiological features, and trends in the SENTRY antimicrobial surveillance program (1997-1999). Clin Infect Dis 32:104-113, 2001 (suppl 2)